ストックスクリーナーアプリを入手
0.5215
3.41%
-0.0184
アフターアワーズ：
.53
0.0085
+1.63%
前日終値:
$0.5399
開ける：
$0.5168
24時間の取引高:
40,734
Relative Volume:
0.89
時価総額：
$11.17M
収益：
$2.82M
当期純損益:
$-14.20M
株価収益率:
-0.6135
EPS:
-0.85
ネットキャッシュフロー:
$-15.13M
1週間 パフォーマンス:
-4.31%
1か月 パフォーマンス:
+4.30%
6か月 パフォーマンス:
-42.69%
1年 パフォーマンス:
-48.62%
1日の値動き範囲:
$0.51
$0.5449
1週間の範囲:
$0.50
$0.56
52週間の値動き範囲:
$0.45
$1.27
Talphera Inc Stock (TLPH) Company Profile
TLPH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.5215 | 11.17M | 2.82M | -14.20M | -15.13M | -0.85 |
|
ZTS
Zoetis Inc
|
161.92 | 70.37B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.19 | 48.41B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
10.71 | 47.91B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.96 | 18.80B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
310.80 | 13.47B | 2.76B | 1.11B | 898.10M | 22.77 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2020-07-20 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2019-11-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-05 | 再開されました | Credit Suisse | Outperform |
| 2019-07-10 | 再開されました | Credit Suisse | Outperform |
| 2019-04-24 | 再開されました | B. Riley FBR | Buy |
| 2019-02-15 | 開始されました | Credit Suisse | Outperform |
| 2018-10-23 | 開始されました | B. Riley FBR | Buy |
| 2017-10-13 | ダウングレード | Jefferies | Buy → Hold |
| 2017-10-13 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-07-14 | 再開されました | Jefferies | Buy |
| 2016-09-15 | 繰り返されました | ROTH Capital | Buy |
| 2016-08-05 | ダウングレード | Stifel | Buy → Hold |
| 2015-10-30 | アップグレード | Jefferies | Hold → Buy |
| 2015-10-05 | 繰り返されました | ROTH Capital | Buy |
| 2015-09-02 | 開始されました | H.C. Wainwright | Buy |
| 2015-07-10 | 再開されました | ROTH Capital | Buy |
| 2015-05-06 | 繰り返されました | Mizuho | Neutral |
| 2015-05-05 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-03-10 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-03-09 | ダウングレード | Mizuho | Buy → Neutral |
すべてを表示
Talphera Inc (TLPH) 最新ニュース
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 - Citizen Tribune
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 | TLPH Stock News - GuruFocus
All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy - Yahoo Finance
HC Wainwright Predicts Talphera’s Q1 Earnings (NASDAQ:TLPH) - Defense World
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
HC Wainwright Estimates Talphera FY2029 Earnings - Defense World
Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks
Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com Canada
Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com
Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World
Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada
Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India
Talphera: Q4 Earnings Snapshot - CT Insider
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance
Talphera Reports 2024 Financial Results and Study Update - TipRanks
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India
FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK
TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
TALPHERA, INC. SEC 10-K Report - TradingView
Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA approves Talphera’s reduced NEPHRO CRRT study size - Investing.com India
Talphera reports Q4 EPS (7c) vs. (25c) last year - TipRanks
FDA Green Light: Talphera Slashes Trial Size by 58% as Q4 Losses Drop 57% - Stock Titan
TLPH stock touches 52-week low at $0.5 amid market challenges - Investing.com
Talphera to Reduce Size of Renal Replacement Therapy Study, Enters Private Placement; Shares Fall - MarketScreener
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million - PR Newswire
Earnings Outlook For Talphera - Benzinga
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 - Longview News-Journal
Talphera to Unveil 2024 Performance: Key Financial Results and Strategic Updates Coming March 31 - Stock Titan
Talphera Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Talphera (TLPH) Expected to Announce Earnings on Wednesday - Defense World
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock By Investing.com - Investing.com South Africa
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock - Investing.com
Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened - Armenian Reporter
Talphera Inc (NASDAQ: TLPH) Is On The Rise - Stocks Register
RODMAN&RENSHAW Upgrades Talphera (NASDAQ:TLPH) to Strong-Buy - Defense World
Rodman & Renshaw sets Talphera stock Buy rating, $4 target - MSN
Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright - Defense World
FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada
FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria
FDA to review Talphera's request to amend NEPHRO study - Investing.com
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - The Eastern Progress Online
Talphera Inc (TLPH) 財務データ
収益
当期純利益
現金流量
EPS
3.78%
2.72%
大文字化:
|
ボリューム (24 時間):